| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/11/2009 | EP2022785A1 Alkynylpyrimidines as Tie2 kinase inhibitors |
| 02/11/2009 | EP2022784A1 Process for the preparation of methyl ester of rosuvastatin |
| 02/11/2009 | EP2022783A1 "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors" |
| 02/11/2009 | EP2022782A1 Process for production of optically active piperidine compound |
| 02/11/2009 | EP2022778A1 A crystalline form of (R,R)-tramadol-(S)-naproxene salt |
| 02/11/2009 | EP2022501A1 Use of phytate as agent inhibiting dissolution of crystals of calcium salts for the prevention of osteoporosis |
| 02/11/2009 | EP2022500A1 Tumor suppressor |
| 02/11/2009 | EP2022499A1 Method for treatment of depression and depressive mood disorders |
| 02/11/2009 | EP2022498A2 Neuroendocrine tumour treatment |
| 02/11/2009 | EP2022497A1 Oral composition comprising 3-[5-[4-(cyclopentyloxy) -2-hydroxybenzoyl]-2-](3-hydroxy-1,2-benzisoxazol-6- yl)methoxy¨phenyl¨propionic acid or salt thereof |
| 02/11/2009 | EP2022496A1 Stable ropinirole compositions |
| 02/11/2009 | EP2022495A1 Composition for preventing the occurrence of cardiovascular event in multiple risk patient |
| 02/11/2009 | EP2022494A2 Laxative preparation containing l-Arginine |
| 02/11/2009 | EP2022493A1 Composition comprising at least one optically active phthalamide derivative for controlling animal parasites |
| 02/11/2009 | EP2022492A1 Anti-cancer pharmaceutical composition |
| 02/11/2009 | EP2022345A1 Food composition for functional foods and nutritional supplements |
| 02/11/2009 | EP2022344A1 Reduction of fatigue as a result of exercise |
| 02/11/2009 | EP2021797A2 Compositions of n-ý2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl¨-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| 02/11/2009 | EP2021502A1 Novel genes and markers in type 2 diabetes and obesity |
| 02/11/2009 | EP2021496A2 Compositions and methods for detecting and treating hiv infection |
| 02/11/2009 | EP2021472A2 Compounds and methods for modulating gene expression |
| 02/11/2009 | EP2021363A1 Polypeptides and polynucleotides encoding the same |
| 02/11/2009 | EP2021351A2 Method for the synthesis of triazole-containing oligonucleotide derivatives |
| 02/11/2009 | EP2021350A1 Phosphorylated a2a receptor agonists |
| 02/11/2009 | EP2021343A1 Imidazoazephinone compounds |
| 02/11/2009 | EP2021342A1 PYRIDO[3,2-e]PYRAZINES, THEIR USE AS INHIBITORS OF PHOSPHODIESTERASE 10, AND PROCESSES FOR PREPARING THEM |
| 02/11/2009 | EP2021341A1 4-AMINO-PYRIDOÝ3,2-e¨PYRAZINES, THEIR USE AS INHIBITORS OF PHOSPHODIESTERASE 10, AND PROCESSES FOR PREPARING THEM |
| 02/11/2009 | EP2021339A1 Rosiglitazone hydrochloride hemihydrate |
| 02/11/2009 | EP2021338A1 Cycloalkylamino acid derivatives and pharmaceutical compositions thereof |
| 02/11/2009 | EP2021337A2 Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
| 02/11/2009 | EP2021336A2 Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
| 02/11/2009 | EP2021335A1 Heterocyclic compounds as inhibitors of c-fms kinase |
| 02/11/2009 | EP2021334A1 Synthesis and uses of pyroglutamic acid derivatives |
| 02/11/2009 | EP2021333A2 Anti-proliferative compounds deriving from a 3-aryl-coumarine or 3-aryl-quinolin-2-one and uses thereof |
| 02/11/2009 | EP2021331A1 2-phenyl-5-amino-1,3,4-oxadiazoles and their use as nicotinic acetylcholine receptor ligands |
| 02/11/2009 | EP2021330A2 Benzimidazole modulators of vr1 |
| 02/11/2009 | EP2021329A1 Inhibitors of c-fms kinase |
| 02/11/2009 | EP2021327A2 Antidiabetic bicyclic compounds |
| 02/11/2009 | EP2021326A1 Polymorph forms of (2s) - (4e) -n-methyl-5- (3-isopropoxypyridin) yl]-4-penten-2-amine for the treatment of central nervous system disorders |
| 02/11/2009 | EP2021324A1 Nitrated heterocyclic compounds as endothelin receptor antagonist |
| 02/11/2009 | EP2021322A2 Therapeutic cyclopentane derivatives |
| 02/11/2009 | EP2021321A2 2-methylene-1alpha,25-dihydroxy-18,19,21-trinorvitamin d3 and uses thereof |
| 02/11/2009 | EP2021320A2 2-substituted-1alpha, 25-dihydroxy-19,26,27-trinor vitamin d analogs and uses thereof |
| 02/11/2009 | EP2021317A1 Contrast agents |
| 02/11/2009 | EP2021316A1 Inhibitors of polo-like kinases |
| 02/11/2009 | EP2021314A1 Substituted biphenyl carboxylic acids and derivatives thereof |
| 02/11/2009 | EP2021078A1 Sulphated hyaluronic acid for treating degenerative osteoarthritis |
| 02/11/2009 | EP2021028A2 Methods and compositions for modulation of blood-neural barrier |
| 02/11/2009 | EP2021012A1 Combination of amino acid solution and a gelatin derivative for inhibiting renal uptake |
| 02/11/2009 | EP2021010A1 Condensation products, method for their production and use thereof in medicaments, as disinfectants or as a tannin |
| 02/11/2009 | EP2021007A2 Patch for the treatment of the cellulite and localized adiposity |
| 02/11/2009 | EP2021006A2 Use of flibanserin for the treatment of post-menopausal sexual desire disorders |
| 02/11/2009 | EP2021005A1 Methods and composition for treatment of inflammatory pain |
| 02/11/2009 | EP2021004A2 Substituted azaspiro derivatives |
| 02/11/2009 | EP2021003A2 Imidazoazephinone compounds |
| 02/11/2009 | EP2021002A2 Pharmaceutical composition |
| 02/11/2009 | EP2021001A2 Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation |
| 02/11/2009 | EP2021000A2 Neurogenesis by modulating angiotensin |
| 02/11/2009 | EP2020999A1 Compositions comprising alpha-ketoglutarate and their use for modulating muscle performance |
| 02/11/2009 | EP2020998A1 Compositions and methods for the inhibition of endothelial nitric oxide synthase activity |
| 02/11/2009 | EP2020997A2 Novel actives against prostate carcinoma |
| 02/11/2009 | EP2020996A2 Method and compositions for treating hematological malignancies |
| 02/11/2009 | EP2020995A2 Zero-order modified release solid dosage forms |
| 02/11/2009 | EP2020994A2 Sustained release pharmaceutical dosage form containing phenylephrine |
| 02/11/2009 | EP2020993A2 Solid pharmaceutical composition of gabapentin |
| 02/11/2009 | EP2020991A2 A direct cellular energy delivery system |
| 02/11/2009 | EP2020989A2 Pulmonary delivery of 1,25-dihydroxyvitamin d3 and co-administration of parathyroid hormone or calcitonin |
| 02/11/2009 | EP2020970A1 Eye treatment |
| 02/11/2009 | EP2020874A1 Composition comprising one or more esterified phytosterols and/or phytostanols into which are solubilized one or more unesterified phytosterols and/or phytostanols, in order to achieve therapeutic and formulation benefits |
| 02/11/2009 | EP2020873A2 Food products for hypophosphoric normo-, hyper- and hypoproteic diets, and their use for nutrition of subjects in need of a low phosphorus level diet |
| 02/11/2009 | EP2020869A1 Hydroxybutyrate and poly-hydroxybutyrate as components of animal feed or feed additives |
| 02/11/2009 | EP2020857A2 Antimicrobial therapy for bacterial infections |
| 02/11/2009 | EP2020851A2 Substituted aromatic heterocyclic compounds as fungicides |
| 02/11/2009 | EP2020849A2 Preparation and utility of substituted carboxylic acid compounds |
| 02/11/2009 | EP1937221B1 Retard formulation for pralnacasan |
| 02/11/2009 | EP1853601B1 Non steroidal glucocorticoid receptor modulators |
| 02/11/2009 | EP1851217B1 Substituted pyrido[2,3-d]pyrimidine derivatives useful as medicines for the treatment of autoimmune disorders |
| 02/11/2009 | EP1819709B1 Novel diazabicyclic aryl derivatives as cholinergy ligands |
| 02/11/2009 | EP1748792B1 Compositions comprising demethylating agents as enhancers of immunotherapy for the treatment of chronic infections and neoplastic diseases and methods for treating the same |
| 02/11/2009 | EP1747262A4 Conserved inner core lipopolysaccharide epitopes as multi-species vaccine candidates |
| 02/11/2009 | EP1663168B1 Nicotine formulations and use thereof |
| 02/11/2009 | EP1622601B1 Pharmaceutical compositions |
| 02/11/2009 | EP1605938B1 Antibacterial derivatives of napthydrin and quinoline |
| 02/11/2009 | EP1581236A4 Sustained release of antiinfectives |
| 02/11/2009 | EP1480687B1 Modified phosphocalcic compound, injectable composition containing same |
| 02/11/2009 | EP1478236B1 Targeted retrograde gene delivery to motor neurons |
| 02/11/2009 | EP1458747B1 Template-fixed peptidomimetics as inhibitors of serine proteases |
| 02/11/2009 | EP1439855A4 Composition and method for minimizing or avoiding adverse effects of vesicants |
| 02/11/2009 | EP1429800B1 Vaccine and use thereof for treatment of amyotrophic lateral sclerosis |
| 02/11/2009 | EP1370561B1 Tetrahydro-pyrazino[1,2-a]indoles for the treatment of central nervous disorders |
| 02/11/2009 | EP1317258B1 Use of allopurinol for the treatment of hypertension |
| 02/11/2009 | EP1228063B1 Substituted pyridines and pyridazines with angiogenesis inhibiting activity |
| 02/11/2009 | CN101365801A Compositions and methods for inhibiting expression of huntingtin gene |
| 02/11/2009 | CN101365798A Novel K04-0144 substance and preparation thereof |
| 02/11/2009 | CN101365778A Clleasing composition |
| 02/11/2009 | CN101365767A Polycationic viscoelastic compositions |
| 02/11/2009 | CN101365708A Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1h-1,2,4-triazol-1-yl)-1-[(phosphonooxy)methyl]-1h-pyrrolo[2,3-c]pyridin-3-yl]-1,2-dioxoethyl]-piperazine |
| 02/11/2009 | CN101365704A Lestaurtinib crystalline form 1, crystalline lestaurimib anhydrate and amorphous lestaurimib |
| 02/11/2009 | CN101365703A Heteroalkyl linked pyrimidine derivatives |
| 02/11/2009 | CN101365702A Inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applications |